Tamoxifen
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00675 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | mammary Paget disease | KG + DL |
| 2 | intraductal cribriform breast adenocarcinoma | KG + DL |
| 3 | basal-like breast carcinoma | KG + DL |
| 4 | breast carcinoma in situ | KG + DL |
| 5 | sebaceous breast carcinoma | KG + DL |
| 6 | invasive tubular breast carcinoma | KG + DL |
| 7 | hormone-resistant breast carcinoma | KG + DL |
| 8 | Ehrlich tumor carcinoma | KG + DL |
| 9 | estrogen-receptor positive breast cancer | KG + DL |
| 10 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 11 | estrogen-receptor negative breast cancer | KG + DL |
| 12 | adenoid cystic breast carcinoma | KG + DL |
| 13 | scirrhous breast carcinoma | KG + DL |
| 14 | medullary breast carcinoma | KG + DL |
| 15 | prostate cancer/brain cancer susceptibility | KG + DL |
| 16 | lobular breast carcinoma in situ | KG + DL |
| 17 | oncocytic breast carcinoma | KG + DL |
| 18 | adenocarcinoma in situ | KG + DL |
| 19 | mucoepidermoid breast carcinoma | KG + DL |
| 20 | breast malignant eccrine spiradenoma | KG + DL |
| 21 | invasive ductal and lobular carcinoma | KG + DL |
| 22 | signet ring cell breast carcinoma | KG + DL |
| 23 | breast intraductal proliferative lesion | KG + DL |
| 24 | fibroma of prostate | KG + DL |
| 25 | dermatofibrosarcoma protuberans | KG + DL |
| 26 | breast mucinous cystadenocarcinoma | KG + DL |
| 27 | bilateral breast carcinoma | KG + DL |
| 28 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 29 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 30 | Brenner tumor | KG + DL |
| 31 | benign reproductive system neoplasm | KG + DL |
| 32 | rhabdomyosarcoma (disease) | KG + DL |
| 33 | prostate leiomyoma | KG + DL |
| 34 | breast carcinoma by gene expression profile | KG + DL |
| 35 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 36 | breast secretory carcinoma | KG + DL |
| 37 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 38 | male reproductive organ cancer | KG + DL |
| 39 | fibroblastic neoplasm | KG + DL |
| 40 | liver sarcoma | KG + DL |
| 41 | heart fibrosarcoma | KG + DL |
| 42 | liposarcoma | KG + DL |
| 43 | benign prostate phyllodes tumor | KG + DL |
| 44 | kidney fibrosarcoma | KG + DL |
| 45 | ovarian myxoid liposarcoma | KG + DL |
| 46 | breast columnar cell mucinous carcinoma | KG + DL |
| 47 | nipple carcinoma | KG + DL |
| 48 | clear cell renal carcinoma | KG + DL |
| 49 | conventional fibrosarcoma | KG + DL |
| 50 | low grade fibromyxoid sarcoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.